Skip to main content

Table 2 Primary and main secondary outcomes at days 4 and 90 in participants diagnosed with a stroke mimic. Data are number (%), median [IQR], or mean (standard deviation)

From: Pre-hospital transdermal glyceryl trinitrate in patients with stroke mimics: data from the RIGHT-2 randomised-controlled ambulance trial

 

N

GTN

Sham

aOR/aMD (95% CI), adjusted

p-value

Day 90 mRS (/6)

 All

274

3 [1,4]

3 [1,4]

0.5 (0.3, 0.9)

0.008

Sensitivity analyses

 Per-protocol

245

3 [1,4]

3 [1,4]

0.6 (0.4, 0.9)

0.026

 With multiple imputation

297

3 [1,4]

3 [1,4]

0.6 (0.4, 0.9)

0.013

 mean mRS

274

2.5 (1.7)

2.8 (1.9)

−0.5 (− 0.8, − 0.1)

0.012

 mRS, unadjusted

274

3 [1,4]

3 [1,4]

0.8 (0.5, 1.2)

0.27

 mRS > 2 (%)

274

72 (58.1)

91 (60.7)

0.6 (0.3, 1.2)

0.18

 mRS > 2, unadjusted (%)

274

72 (58.1)

91 (60.7)

0.9 (0.6, 1.5)

0.66

 mRS, Received thrombolysis

8

1 [1,2]

1 [0,1]

–

–

 mRS, No thrombolysis

266

3 [1,4]

3 [1,4]

0.6 (0.4, 0.9)

0.013

Admission

 NIHSS (/42)

176

5.7 (6.2)

5.3 (5.3)

−0.2 (−1.8, 1.4)

0.82

 FAST (hospital admission) [/3]

186

1.4 (1.1)

1.5 (1.0)

−0.2 (− 0.5, 0.1)

0.19

 OCSP, TACS (%)

224

15 (15.8)

25 (19.4)

0.8 (0.4, 1.7)

0.57

 GCS admission

241

14.4 (1.4)

14.2 (1.8)

0.3 (−0.1, 0.7)

0.13

Day 4 (or discharge)

 Death (%)

279

2 (1.6)

1 (0.6)

2.2 (0.2, 29.8)

0.56

 Patients with an SAE (%)

279

6 (4.8)

10 (6.5)

0.8 (0.3, 2.5)

0.73

 Infection (%)

275

11 (8.9)

17 (11.3)

0.5 (0.2, 1.2)

0.13

 Neurological deterioration (%)

52

2 (7.7)

3 (11.5)

0.1 (0.0, 10.4)

0.27

 Neurological deterioration, clinical (%)

275

6 (4.8)

4 (2.6)

2.3 (0.6, 9.4)

0.25

 Headache (%)

274

8 (6.5)

8 (5.3)

1.4 (0.5, 4.1)

0.54

 Hypotension, SBP < 90 mmHg (%)

274

3 (2.4)

0 (0)

–

–

 Hypertension, SBP > 180 mmHg (%)

274

17 (13.8)

15 (9.9)

2.1 (0.9, 4.9)

0.090

 Feeding: non-oral (%)

243

7 (6.4)

7 (5.3)

1.1 (0.4, 3.5)

0.87

 Glasgow coma scale (/15)

114

14.2 (2.5)

14.2 (2.7)

0.1 (−0.9, 1.1)

0.79

 NIHSS (/43)

57

4.5 (10.9)

4.9 (9.7)

−0.6 (−6.4, 5.3)

0.85

Hospital events

 Length of stay (days)

279

4.8 (8.5)

5 (6.9)

−0.6 (−2.4, 1.1)

0.48

 Died in hospital (%)

279

6 (4.8)

3 (1.9)

3.7 (0.8, 17.1)

0.098

 Died or discharged to institution (%)

271

13 (10.8)

19 (12.6)

0.8 (0.3, 1.7)

0.49

Day 90

 Death (%)

281

8 (6.3)

19 (12.3)

0.5 (0.2, 1.2)

0.11

 Disposition (%)

260

1 [1,1]

1 [1,1]

0.6 (0.3, 1.2)

0.14

 EQ-5D HUS (/1)

257

0.5 (0.4)

0.5 (0.4)

0.1 (0.0, 0.2)

0.031

 Quality of life, EQ-VAS (/100)

240

57.3 (25.8)

51.9 (30.3)

6.5 (−0.2, 13.3)

0.057

 Barthel Index (/100)

253

75.2 (35.1)

71.7 (39.2)

6.3 (−1.4, 14.0)

0.11

 Disability, Barthel index < 60 (%)

253

27 (23.9)

33 (23.6)

0.9 (0.4, 1.9)

0.73

 TICS-M

112

19.3 (10.5)

15 (11.0)

3.3 (−0.0, 6.5)

0.052

 tMMSE

116

15.5 (8.0)

12.7 (9.0)

2.4 (−0.1, 4.9)

0.061

 Animal naming

114

14.7 (9.5)

11.8 (10.1)

1.7 (−1.3, 4.7)

0.26

 Zung Depression Scale (/100)

139

62.5 (24.3)

62.4 (27.1)

−2.3 (−9.9, 5.3)

0.55

 Home time (days)

221

91 (36.2)

85.7 (39.7)

6.3 (−3.0, 15.7)

0.19

 Global analysis

112

–

–

−0.1 (−0.2, 0.0)

0.15

  1. aMD adjusted mean difference, aOR adjusted odds ratio, CI confidence interval, EQ-5D HUS EuroQol EQ-5D Health utility scores, FAST face-arm-speech test, GCS Glasgow Coma Scale, GTN glyceryl trinitrate, mmHg millimetres of mercury, MI multiple imputation, mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, OCSP Oxford Community Stroke Project classification, PP per protocol analysis, SAE serious adverse event, TACS total anterior circulation stroke, TICS-M Telephone Interview for Cognitive Status -Modified, t-MMSE modified telephone Mini-Mental State Examination